Skip to content
value.today

Ropharma SA: financial analysis

Ratios worked out from 3 fiscal years of Ropharma SA's statements.

The newest statement on file is for fiscal 2021. The figures below describe that year, not Ropharma SA today.

Operating margin, 2021
2.4%
Return on equity, 2021
5.4%
Free cash flow margin, 2021
-2.4%

Ropharma SA scorecard#

Passes 1 of the 2 checks that could be worked out. Fiscal year 2021.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 2
    • ✓Profitable in the newest year$3 MNet income $3 M in fiscal 2021.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianToo few peers for a median.
    • ✗Return on equity above 15%5.3%5.3% in fiscal 2021.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (esef), the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2021 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Free cash flow was negative: -$4 million.
  • Only -11% of net income arrived as cash from operations.

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin1.4%Asset turnover1.22×Assets to equity3.18×Return on equity5.4%

Profitability#

Ropharma SA: profitability by fiscal year
Fiscal yearTrend202120202019
Operating margin2.4%——
Net margin1.4%——
Return on equity5.4%——
Return on assets1.7%——

Financial strength#

Ropharma SA: financial strength by fiscal year
Fiscal yearTrend202120202019
Equity share of assets32.9%——

Cash#

Ropharma SA: cash by fiscal year
Fiscal yearTrend202120202019
Free cash flow$-4 M——
Free cash flow margin-2.4%——
Cash conversion-10.9%——
Capital spending share of revenue2.2%——

Efficiency#

Ropharma SA: efficiency by fiscal year
Fiscal yearTrend202120202019
Asset turnover1.22×——

How each figure is worked out#

Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Asset turnover
Revenue divided by total assets (average of the year).